Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials
File version
Author(s)
McInnes, Iain B
Kavanaugh, Arthur
Nash, Peter
Xue, Zhenyi
Stakias, Vassilis
Eldred, Ann
Ciecinski, Sandra
Douglas, Kevin
Coates, Laura
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Philadelphia, USA
License
Abstract
Background/Purpose: Risankizumab (RZB) is a monoclonal antibody that specifically inhibits interleukin 23.
Methods: KEEPsAKE-1 and -2, double-blind, phase 3 trials, evaluated the efficacy of RZB versus placebo (PBO) for the treatment of adult patients with active psoriatic arthritis (PsA). Patients were randomized (1:1) to receive subcutaneous RZB 150 mg or PBO at weeks 0, 4, and 16. The open label extension began at Week 24 with all patients receiving RZB 150 mg every 12 weeks thereafter. Achievement of Minimal Disease Activity (MDA), its components, and achievement of Disease Activity in PsA Low Disease Activity and Remission (DAPSA LDA+REM, [DAPSA score ≤14]) are reported using non-responder imputation.
Results: MDA achievement at Week 52 in KEEPsAKE-1 was 37.9% for patients originally randomized to RZB and 27.4% for patients originally randomized to PBO. In KEEPsAKE-2, MDA achievement was 27.2% and 33.8% for patients originally randomized to RZB and PBO, respectively. Achievement of MDA and its components are presented in Figure 1. In KEEPsAKE-1, at Week 52 59.2% of patients originally randomized to RZB and 51.4% of patients originally randomized to PBO achieved DAPSA LDA+REM. At Week 52 in KEEPsAKE-2, DAPSA LDA+REM was achieved by 44.6% of patients originally randomized to RZB and 46.6% of patients originally randomized to PBO (Figure 1).
Conclusion: Patients treated with RZB demonstrate achievement of MDA, its components, and DAPSA LDA+REM at Weeks 24 and 52.
Journal Title
Conference Title
Arthritis & Rheumatology
Book Title
Edition
Volume
74
Issue
S9
Thesis Type
Degree Program
School
Publisher link
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Rheumatology and arthritis
Pharmacology and pharmaceutical sciences
Clinical sciences
Public health
Life Sciences & Biomedicine
Rheumatology
Science & Technology
Persistent link to this record
Citation
Merola, J; McInnes, IB; Kavanaugh, A; Nash, P; Xue, Z; Stakias, V; Eldred, A; Ciecinski, S; Douglas, K; Coates, L, Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials, Arthritis & Rheumatology, 2022, 74 (S9), pp. 4211-4212